Semaglutide vs Tirzepatide: Which One Actually Wins?
Both molecules work. The question isn't which one is good — it's which one is right for you, at what price, with what side-effect trade-off. Here's the direct comparison, not the drug-class primer.
Tirzepatide produced a bigger average result than semaglutide in the first true head-to-head trial — about 20% of body weight lost at 72 weeks versus about 14%, per the 2025 SURMOUNT-5 data. Semaglutide costs less at every access tier and has years more real-world use behind it. Side effects overlap heavily in type and severity, with a slight edge to tirzepatide on discontinuation rates in that same trial. Neither drug is the universal answer — which one wins for you depends on how much that extra average result is worth against the extra cost, detailed by profile below.
What you'll actually pay
Cheapest verified compounded semaglutide — medication, consult, and shipping in one price. 503A individual-patient pathway.
See pricesCheapest verified compounded tirzepatide — all-in, no separate membership fee. 503A pathway; starter-dose rate.
See pricesFDA-approved semaglutide injection, shipped direct from Novo Nordisk. No compounding involved.
See pricesFDA-approved tirzepatide vials, shipped direct from Lilly. Refill within 45 days to hold the rate.
See pricesRequires commercial insurance covering Wegovy for obesity. Cannot combine with Medicare/Medicaid.
See pricesRequires commercial insurance covering Zepbound for obesity; comorbidity documentation often needed for approval.
See pricesIs tirzepatide actually better than semaglutide?
In May 2025, the question got an answer that didn't depend on comparing two separate trials run years apart. SURMOUNT-5 randomized adults with obesity to either drug for 72 weeks under the same protocol and measured what happened to both groups side by side, with results published in the New England Journal of Medicine. Tirzepatide produced a mean weight change of about 20% of starting body weight. Semaglutide produced about 14%. Waist circumference fell further with tirzepatide too, and roughly 20% of the tirzepatide group lost at least 30% of their body weight, compared with about 7% on semaglutide.
One thing dates that headline. SURMOUNT-5 ran semaglutide at a maximum tolerated 1.7 or 2.4mg, the top of its range at the time; in March 2026 the FDA approved a higher 7.2mg strength that reached about 20.7% average weight loss in a trial of its own. That narrows the gap rather than closing the question — the two figures come from separate trials with different participants, and nobody has yet run tirzepatide against semaglutide at 7.2mg. The higher dose is also a step up rather than a starting point, cleared for people who have already tolerated 2.4mg for at least a month, and gastrointestinal side effects turned up more often at that strength.
Those numbers are trial averages, not a promise for any individual — results vary with dose, adherence, diet, and physiology. But on the narrow question of average effect size in a direct comparison, tirzepatide still holds the only head-to-head win either molecule has; what semaglutide's newer dose puts in question is the size of that lead, not its existence.
What's the real difference between semaglutide and tirzepatide?
The gap traces back to mechanism. Semaglutide acts on a single target — the GLP-1 receptor — which slows stomach emptying, boosts insulin release after meals, and quiets appetite signaling in the brain. Tirzepatide does all of that too, but adds a second receptor, GIP, that appears to compound the effect on appetite and possibly on how the body handles fat and blood sugar together. Researchers sometimes call tirzepatide a 'twincretin' — two incretin hormones mimicked by one molecule instead of one. That dual action is the leading explanation for tirzepatide's edge in SURMOUNT-5, though exactly how much comes from the extra receptor versus the specific doses tested is still being studied.
Semaglutide vs tirzepatide side effects — is one easier to tolerate?
Both drugs cause the same family of side effects, for the same underlying reason: slowing digestion is the mechanism, not an accident of it. Nausea, vomiting, diarrhea, and constipation are the most commonly reported issues with both, and they cluster hardest in the first couple of months after a dose increase before typically easing.
In SURMOUNT-5, gastrointestinal side effects severe enough to stop treatment happened more often on semaglutide than tirzepatide — about 5.6% versus 2.7% of participants. Some separate trial and real-world data suggest a difference in which symptom shows up more: semaglutide skewing slightly toward nausea and constipation, tirzepatide skewing slightly toward looser stools. Neither pattern is universal, and plenty of women tolerate one drug better than the other for reasons that don't show up cleanly in trial averages.
Which one costs less — compounded, brand, or with insurance?
Semaglutide wins on price at every tier. Compounded semaglutide starts lower than compounded tirzepatide, brand Wegovy self-pay starts lower than brand Zepbound self-pay, and the gap holds even between the cheapest verified program for each. The table above lines up the comparable tiers side by side. For the full pathway-by-pathway breakdown, including every provider we've checked, see our semaglutide cost guide and tirzepatide cost guide.
Insurance changes the math entirely. If your plan covers either drug for obesity and you qualify for the manufacturer's savings card, both land around $25 a month. At that point cost stops being the deciding factor, and efficacy or side-effect tolerance should drive the choice instead.
Which one is right for you? Verdict by profile
- You want the strongest average result and cost is secondary: tirzepatide's head-to-head edge in SURMOUNT-5 is the best evidence either drug has for a bigger average outcome, though semaglutide's newer 7.2mg dose has since narrowed that margin — still worth the modest cost premium if the result matters more to you than the price gap.
- Budget is the deciding factor: semaglutide is cheaper at every access tier, compounded or brand, and for many women the difference between a 14% and a 20% average result matters less than a few hundred dollars a month.
- You've struggled with nausea on a GLP-1 before: the trial-level discontinuation data gives tirzepatide a slight edge on tolerability, though this varies person to person and isn't a guarantee.
- You want the longest track record: semaglutide has been on the market longer — Ozempic since 2017, Wegovy since 2021 — versus tirzepatide's 2022 (Mounjaro) and 2023 (Zepbound) approvals. More years in circulation means more accumulated real-world safety data.
Semaglutide oral vs injection — does that change the comparison?
If avoiding injections matters to you, semaglutide currently has more oral ground to stand on. Rybelsus — an FDA-approved oral semaglutide tablet indicated for type 2 diabetes — produces a more modest weight effect than the injectable form, and it comes with a strict routine: taken on an empty stomach with a small amount of water, then a wait before eating or taking anything else. Compounded oral semaglutide also exists as sublingual troches through some telehealth pharmacies, though these are compounded formulations, not FDA-approved products, and their absorption differs from a swallowed tablet.
Tirzepatide has no FDA-approved oral version as of 2026 — its peptide structure doesn't survive digestion intact, which is why Zepbound and Mounjaro remain injection-only. Eli Lilly's oral pill, approved in 2026 under the brand name Foundayo (orforglipron), targets only the GLP-1 receptor and is a chemically distinct small-molecule drug, not oral tirzepatide. So if a pill is a hard requirement, semaglutide is the molecule of the two with an actual oral pathway today, whether that's Rybelsus or a compounded troche.
Can you switch from semaglutide to tirzepatide (or the reverse)?
Yes — clinicians make this switch routinely when a plateau shows up or side effects become hard to live with. There's no FDA-established dose equivalency between the two drugs, so a switch isn't a matter of converting your current dose to an equivalent one. In practice, most prescribers restart the new drug at its lowest introductory level rather than matching where you left off on the old one, and time the transition around each drug's weekly dosing schedule so there isn't an overlap. How that's managed — timing, monitoring, what to expect in the first few weeks — is worth working through with whoever is prescribing, since it varies by provider and by how you responded to the first drug.
Is compounded semaglutide or tirzepatide the safer/more legitimate choice?
Neither has a broad compounding allowance anymore. Both molecules were compounded at scale during their respective FDA shortage designations, and both of those shortages have since been declared resolved — semaglutide earlier in the cycle, tirzepatide in December 2024, with enforcement discretion for 503A pharmacies ending in February 2025 and for 503B outsourcing facilities in March 2025. What remains for both drugs is a narrower 503A individual-patient pathway: a compounding pharmacy preparing the medication for a specific patient with a documented clinical reason the FDA-approved version won't work for them.
In practical terms, that means the legitimacy question isn't really 'semaglutide vs. tirzepatide' — it's about the individual pharmacy and provider on either side of that transaction. Look for PCAB-accredited pharmacies, clear sourcing, and a provider willing to explain how they document medical necessity for either drug. That standard applies equally to both molecules.
Semaglutide vs tirzepatide for perimenopause and menopause weight gain
The weight shift that shows up in perimenopause has a specific hormonal driver: falling estrogen worsens insulin resistance and pushes fat storage toward the abdomen, on top of whatever else is going on in a woman's life at 40-plus. Both drugs act on pathways relevant to that shift — improving insulin sensitivity and reducing appetite signaling — which is why obesity-medicine physicians increasingly view GLP-1 medications as reasonably well matched to the perimenopausal metabolic environment, not just generic weight-loss tools.
No trial has directly compared semaglutide and tirzepatide specifically in a perimenopausal or postmenopausal population, so there isn't a menopause-specific verdict to report — the SURMOUNT-5 comparison above is the best head-to-head evidence available, and it wasn't designed around menopausal status. Tirzepatide's added GIP mechanism is a plausible reason it might address insulin resistance somewhat more directly, but that's a mechanistic argument, not a demonstrated result in this population specifically.
Frequently asked questions
Is tirzepatide always better than semaglutide?+–
Not universally — it's better on average trial results. SURMOUNT-5 showed a bigger average weight change with tirzepatide (about 20% vs about 14% at 72 weeks) and a lower rate of GI-related discontinuation. That trial ran semaglutide at 2.4mg or below; a higher 7.2mg dose approved in March 2026 reached about 20.7% in a separate trial, so the real margin today is likely narrower than the head-to-head headline suggests. Semaglutide is also cheaper at every access tier, has a longer real-world track record, and some women simply tolerate it better individually, which trial averages can't predict for any one person.
Which is cheaper, semaglutide or tirzepatide?+–
Semaglutide, at every tier we've checked. The cheapest verified compounded semaglutide runs $150–$249/mo versus about $199/mo for the cheapest verified compounded tirzepatide, and brand Wegovy self-pay starts lower than brand Zepbound self-pay. With qualifying commercial insurance and a savings card, both land around $25/mo — at that point cost stops differentiating them.
Can I switch from semaglutide to tirzepatide if it stops working?+–
Yes, this is a routine clinical switch when a plateau or intolerable side effects show up. There's no FDA-established dose conversion between the two, so most prescribers restart the new drug at its lowest introductory level rather than matching your prior dose, timing the change around each drug's weekly schedule. The specifics are worth discussing directly with whoever is prescribing.
Is compounded semaglutide or tirzepatide legal in 2026?+–
Both are legal only through a narrower 503A individual-patient pathway now that their respective FDA shortage designations have been resolved — tirzepatide's enforcement discretion ended in February-March 2025. A compounding pharmacy can still prepare either drug for a specific patient with documented clinical need. Confirm with any provider how they source and document the medication before enrolling.
Does tirzepatide work better for menopause weight gain than semaglutide?+–
No trial has compared the two drugs specifically in a perimenopausal or postmenopausal population, so there's no menopause-specific verdict to point to. The general head-to-head data (SURMOUNT-5) favors tirzepatide on average weight loss, and its dual GIP/GLP-1 mechanism is a plausible reason it might address menopause-related insulin resistance somewhat more directly — but that's a mechanistic argument, not a demonstrated result in this specific population.
Which has worse side effects, semaglutide or tirzepatide?+–
They cause the same family of GI side effects — nausea, vomiting, diarrhea, constipation — at broadly similar rates. In the SURMOUNT-5 head-to-head trial, GI-related treatment discontinuation was somewhat more common with semaglutide (5.6%) than tirzepatide (2.7%). Some data suggest semaglutide skews slightly more toward nausea and constipation, tirzepatide slightly more toward loose stools, though individual experience varies.